| The first section:Preliminary studies on Transplantation of umbilical cord mesenchymal stem cells to treat liver cirrhosisBackground: Orthotopic liver transplantation was the most effective way for end-stage liver disease, but the shortage of donor, post-transplant immune rejection as well as the high cost of treatment restricted the treatment of liver transplantation , it was urgent for us to establish a safe and effective treatment. Umbilical cord mesenchymal stem cells transplantation was a new research direction for the treatment of end-stage liver disease.Objective: This study aimed to explore the safety, feasibility and efficacy of umbilical cord mesenchymal stem cells transplantation to the treatment of liver cirrhosis so as to provide a new therapeutic approach to treat end-stage liver disease.Methods: 30 patients who suffered liver cirrhosis were randomly divided into therapy group (16 cases)and control group(14 cases),umbilical cord mesenchymal stem cells transplantation was carried on experimental group (16 cases), based on medical drug treatment; control group(14 cases) carried on medical drug treatment alone. the changes of serum ALB, TBiI, PT and Fbg were detected, at the same time, the patients' symptoms, complications and prognosis were also observed.Results: Serum ALB value in patients of therapy group was higher than that in baseline at 2, 4, 8, and 12 weeks after transplantation (P<0.05). but TBiI value in patients of therapy group was lower than that in baseline at 4, 8, and 12 weeks and PT value in patients of therapy group was lower than that in baseline at 4 and 8weeks after transplantation (P<0.05);there was no significant change on serum TBiI value between 2 weeks after transplantation and baseline in patients of therapy group(P>0.05); Fbg value in patients of therapy group was higher than that in baseline at 8weeks after transplantation (P<0.05) , and there was no significant change on Fbg value beteen 4 weeks after transplantation and baseline in patients of therapy group(P>0.05); there was no significant change on serum ALB, TBiI, PT and Fbg value beteen after transplantation and baseline in patients of control group(P>0.05); After umbilical cord mesenchymal stem cells transplantation, there were no obvious adverse reactions.Conclusions: umbilical cord mesenchymal stem cells transplantation for the treatment of liver cirrhosis was safe and effective in clinic, this measure could improve liver function significantly.It was a good therapeutic approach to treat liver cirrhosis.The second section: Immunomodulatory study of umbilical cord mesenchymal stem cellsBackground: Recent studies found that bone marrow-derived mesenchymal stem cells could not only repair the injured issues, but also play a critical role in immune modulation; And it was applied to treat autoimmune diseases; Immune modulatory mechanisms was related to the promotion of Th2 cytokines (IL-4) secretion and inhibition of Thl cytokines (IFN-γ) secretion , inducing immune tolerance; while Immune modulatory mechanisms of umbilical cord mesenchymal stem cells was rarely reported.Objective: To investigate the immune modulatory mechanisms of umbilical cord mesenchymal stem cells.Methods: Peripheral blood was collected from therapy group (16 cases)and control group(14 cases). serum IFN-γ,IL-4 levels of baseline and after treatment were determined by enzyme-linked immunosorbent assay (ELISA).Results: The level of IFN-γin therapy group on baseline, 7 and 10 days were 291.1±4.3 pg/ml,211.0±4.1 pg/ml,208.6±2.6 pg/ml respectively;and the level of IFN-γ in therapy group on 7 and 10 days after transplantation was significantly lower than that in baseline (P<0.05); The level of IL-4 in therapy group on baseline, 7 and 10 days were 30.3±0.5 pg/ml,50.0±0.7 pg/ml,51.3±0.7pg/ml respectively;and the level of IL-4 in therapy group on 7 and 10 days after transplantation was significantly higher than that in baseline (P<0.05); The level of IFN-γand IL-4 in control group on baseline were 291.6±4.5 pg/ml,30.5±0.9 pg/ml respectively; there was no significant change on serum IFN-γ,IL-4 levels between baseline and after treatment in patients of control group(P>0.05);Conclusion: IFN-γ,IL-4 may play an important role in immune modulation of umbilical cord mesenchymal stem cells. |
PDF Full Text Request